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Abstract
Background: High Resolution Melting Analysis (HRMA) is becoming the preferred method for mutation detection. However,
its accuracy in the individual clinical diagnostic setting is variable. To assess the diagnostic accuracy of HRMA for human
mutations in comparison to DNA sequencing in different routine clinical settings, we have conducted a meta-analysis of
published reports.
Methodology/Principal Findings: Out of 195 publications obtained from the initial search criteria, thirty-four studies
assessing the accuracy of HRMA were included in the meta-analysis. We found that HRMA was a highly sensitive test for
detecting disease-associated mutations in humans. Overall, the summary sensitivity was 97.5% (95% confidence interval (CI):
96.8–98.5; I
2=27.0%). Subgroup analysis showed even higher sensitivity for non-HR-1 instruments (sensitivity 98.7% (95%CI:
97.7–99.3; I
2=0.0%)) and an eligible sample size subgroup (sensitivity 99.3% (95%CI: 98.1–99.8; I
2=0.0%)). HRMA specificity
showed considerable heterogeneity between studies. Sensitivity of the techniques was influenced by sample size and
instrument type but by not sample source or dye type.
Conclusions/Significance: These findings show that HRMA is a highly sensitive, simple and low-cost test to detect human
disease-associated mutations, especially for samples with mutations of low incidence. The burden on DNA sequencing
could be significantly reduced by the implementation of HRMA, but it should be recognized that its sensitivity varies
according to the number of samples with/without mutations, and positive results require DNA sequencing for confirmation.
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Introduction
Although DNA sequencing, including direct DNA sequencing
and pyrosequencing [1], is considered as the ‘‘gold standard’’ for
known/unknown mutation scanning, it still remains relatively
expensive, laborious and time-consuming. Many other methods
for mutation scanning have been developed to screen for
differences between the two copies of DNA within an individual.
These techniques include single-strand conformational polymor-
phism analysis (SSCP) [2], denaturing gradient gel electrophoresis
(DGGE) [3], denaturing high performance liquid chromatography
(DHPLC) [4], temperature gradient capillary electrophoresis
(TGCE) [5] and mass spectroscopy [6]. All of these methods
require separation of the sample on a gel or other matrix.
Fluorescence monitoring of PCR product melting profiles is
another alternative to DNA sequencing that permits the detection
of DNA mutations in solution without the need for separation on a
gel or other matrix [7]. Fluorescently labeled, probe-based
methods, such dual hybridization [8], exonuclease (TaqMan)
[9], or hairpin (Molecular Beacon) [10] probes, may be used for
mutation detection, but only for the bases covered by the probe.
Hence, these methods are not amenable to mutational scanning as
mutational scanning requires methods that can detect mutations
over larger regions. Furthermore, some of the above methods are
not automated and are therefore labor intensive while others are
complex, costly and require specialized instrumentation.
High resolution melting analysis (HRMA) is a simple, PCR-
based method. In the presence of saturating concentrations of
DNA binding dyes, the specific sequence of the amplicon
determines the melting behavior as the temperature of the solution
is increased. Fluorescence intensity decreases as the double
stranded DNA becomes single stranded and the dye is released.
The melting temperature (Tm) at which 50% of the DNA is in the
double stranded state can be approximated by taking the
derivative of the melting curve. The distinctive melting curve
can used to detect DNA sequence variations in the amplicon
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to use, highly sensitive, specific, low cost and yields rapid sample
turn-around [11–13], making HRMA an attractive choice for the
detection of disease-associated mutational variants with applications
in clinical diagnostic labs. Furthermore, HRMA is a nondestructive
method. Therefore, subsequent analysis of the sample by other
techniques, such as gel-electrophoresis or DNA sequencing, can still
be performed after HRMA analysis. These characteristics make
HRMA ideal for use in routine diagnostic settings. Due to its
numerous advantages, HRMA has been widely applied in
diagnostic laboratories for screening for disease-associated muta-
tions. Since it was first introduced for genotyping in 2003 [14],
HRMA has been used to detect mutations such as EGFR [15,16],
KRAS [13,17], KIT [18], BRAF [19,20], BRCA [21], TP53 [22].
In the setting of the EuroGenTest consortium, inter-laboratory
evaluation and validation of HRMA, and generation of guidelines
for implementing the method as a scanning technique for the
discovery of new genes have been proposed [21]. One disadvantage
of HRMA is that the sensitivity and specificity in an individual
clinical diagnostic setting are variable [23]. According to the
‘‘OECD Guidelines for Quality Assurance in Molecular Genetic
Testing’’ [24], there is an obligation for diagnostic laboratories to
provide high quality results. Therefore, all methods implemented
within a routine setting must be duly validated and achieve
acceptable limits for sensitivity and specificity prior to their
diagnostic use. Although reviews and reports on the use of HRMA
for mutation scanning and genotyping have been published
previously [23,25–29], a systematic review of the application of
the technique for diagnostic purposes has not been carried out.
Therefore, the meta-analysis described in this study was performed
to evaluate the diagnostic accuracy of HRMA and investigate the
potential for implementation of HRMA in different routine clinical
settings for the detection of human disease-associated mutations.
The analysis includes a comparison to DNA sequencing. The
purpose of the analysis is to provide clinicians and health managers
with a more objective basis for decision-making regarding
implementation of the technique and to assess areas where there
is currently a lack of evidence regarding the technique [30].
Materials and Methods
Literature search strategy
A literature search was carried out between July and November
2010 using the following databases: Medline, Embase, Cochrane
Library and the Medion databases. The following search words (all
fields)wereused: ‘highresolutionmeltinganalysisorhigh-resolution
fluorescent melting curve analyses or High-resolution amplicon
melting analysis’, ‘HRM or HRMA or HRMCA’, ‘mutation’, and
‘sequence or sequencing’. The CBMdisc databases were used for
Chinese articles with the following keywords (in Chinese): ‘HRM or
HRMA or HRMCA’ and ‘sequencing’. The results were limited to
human species. The date of publication was limited to November 6,
2010. In addition, the following journals were screened manually:
Human Mutation, Cancer Research, Human Molecular Genetics,
Clinical Chemistry, Genetic Testing, Clinical Genetics, Nucleic
Acid Research and the Journal of Medical Genetics and Human
Genetics. Furthermore, the reference lists of the included studies
were screened and additional search engines, including SUM-
search, TRIP database, Sciencedirect, Google, Database for
Chinese Journals of Technology (Chinese) were used. The
applicability of borderline publications was discussed by the authors
until a consensus for inclusion or exclusion was reached. The
Institutional Review Boards approved the conclusion that no ethical
approval was required for this study.
Inclusion and exclusion criteria
The inclusion criteria were as follows: (1) HRMA was applied to
the study of disease-associated mutations in humans, (2) sequenc-
ing (including direct sequencing, dideoxy sequencing or sequenc-
ing of HRM products) was used as a reference standard, (3) only
parts of mutated genes were investigated, (4) only some study data
was compared to direct sequencing as a reference standard (only
this data was included in the current study), (5) sensitivity and
specificity were reported or could be calculated from the results
reported, (6) the authors only reported that there were no false
positive or false negative results, so that conclusions on sensitivity
and specificity could be drawn without calculation of these
parameters, (7) all fragments were included if one gene locus was
amplified into multiple fragments and (8) the publication language
was English or Chinese. The exclusion criteria were as follows: (1)
studies were performed using only HRMA or comparing HRMA
with non-sequencing techniques, (2) HRMA was combined with
other detection methods, such as probes or qPCR, (3) studies used
samples with artificially created sequences, (4) studies were aimed
at detecting polymorphisms. Non-systematic/narrative reviews,
letters, comments, and meeting abstracts were also excluded.
Unpublished sources of data were not included. Publications
identified as duplicates were excluded.
Assessment of Study Quality
The quality of the studies was assessed according to the
‘‘Quality Assessment of Diagnostic Accuracy Studies’’ (QUADAS)
tool [31]. The modified tool was composed of 10 item questions
summarized in Table 1, which were each answered ‘‘yes,’’
‘‘unclear,’’ or ‘‘no.’’ Quality assessment of the studies was carried
out independently by two reviewers (B.S. Li and F.L. Ma). If the
quality assessment of the two reviewers were not in agreement, the
discrepancies were resolved by consensus. The tool does not
incorporate a global quality score. The main reason for this is that
quality scores ignore the importance of individual items and
potential biases related to individual items may vary according to
context. Therefore, the application of quality scores may dilute or
ignore potential associations [31].
Outcome parameters
The outcome parameters were sensitivity, specificity, positive
predictive value and negative predictive value. Two ‘statistical’
units (per amplicon and per sample) and different definitions of
‘positive result’ were accepted as a basis for the calculation of these
parameters. For example, ‘positive’ could mean any alteration,
such as mutations, undetermined melting curves and polymor-
phisms.
Data extraction
The two reviewers (B.S. Li and F.L. Ma) independently
extracted relevant data from each article using a standardized
form (Table S1). The reviewers were not blinded with regard to
information about the journal name, author names, author
affiliations or year of publication since this has previously been
shown to be unnecessary [32]. To resolve disagreement between
reviewers, other authors assessed all discrepant items and the
majority opinion was used for analysis.
Study characteristics
The QUADAS quality assessment tool was used to extract the
relevant study design characteristics of each study (Table 1). In
addition, other main study characteristics were recorded as
follows: (1) year of publication, (2) disease type, (3) sample source,
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mutation-type analyzed, (6) instrument used (7) dye used, (8) level
of analysis (per amplicon and per sample) and (9) length of
sequence (Table 2). The following features were also extracted: (1)
sample size, (2) study site, (3) language and (4) design type.
Examination results
262 tables were extracted on per sample or per amplicon basis,
including the numbers of true-positive, true-negative, false-
positive, and false-negative results in the detection of disease-
associated mutations (Table S1).
Statistical analysis
Combined estimates of sensitivity, specificity, positive and
negative likelihood ratios (LRs) and diagnostic odds ratio (DOR),
together with their 95% confidence intervals (CI), were obtained
from the available data reported in the selected studies
(proportions of true positives, true negatives, false positives and
false negatives). To handle studies with empty cells, 0.5 was added
to all cells from all studies.
The heterogeneity of all indices was evaluated by graphical
examination of forest plots, which are commonly used to detect
heterogeneity in meta-analysis. As meta-analyses include small
numbers of studies, the power of the usual Cochran’s Q test is low.
Therefore, they are poor at detecting true heterogeneity among
studies as significant. An alternative approach to quantify the effect
of heterogeneity is the I
2 index that describes the percentage of
total variation across studies that is due to heterogeneity rather
than chance [33]. I
2 is calculated and a value .50% indicates
substantial heterogeneity [33]. Meta-analyses were performed by
combining the sensitivities, specificities, LRs and DORs using the
DerSimonian-Laird method, a random effects model [34], in
order to incorporate variations among the studies. This approach
was taken because including random effects has been previously
reported as the more realistic and appropriate model for this type
of meta-analysis [35,36]. As a ‘‘threshold effect’’ was not detected
by the Spearman test and the examination of sensitivity and
specificity plots on a receiver operating characteristic (ROC)
plane, summary receiver operating characteristic (SROC) curves
were not constructed [37]. The analyses were carried out using
Microsoft Excel 2003 (Microsoft, Seattle, WA, USA), SPSS 13.0
for Windows (SPSS, Chicago, IL, USA) and Meta-DiSc (Version
1.4) [38].
Meta-regression analysis
Meta-regression analysis was executed to determine whether
diagnostic values were significantly affected by heterogeneity
between the individual studies. First, single factor regression
analysis was performed using variates including instrument type
(HR-1 or other instrument (LightCycler4 80, Rotor-Gene 6000,
LightScanner 96)), level of analysis (per amplicon or per sample),
dye type (EvaGreen, LCGreen I, LCGreen plus, Resolight or
Table 1. ‘‘Quality Assessment of Diagnostic Accuracy
Studies’’ (QUADAS) Tool.
Author 1 2 3 6 8 9 10 11 13 14
Bastien, R. (2008) N Y Y Y Y Y YYYY
Dagar, V. (2009) N Y Y Y Y U U U Y Y
D o , H . ( 2 0 0 8 ) Y Y Y YY Y YYYY
Doi, Y. (2009) N Y Y Y Y N U U Y Y
Fassina, A. (2009) Y Y Y Y U U U U Y Y
Franklin, W.A. (2010) N Y Y Y Y Y U U Y Y
Fukui, T. (2008) N Y Y N
1 U U UUYY
Fuster, O. (2009) N Y Y Y Y Y U U Y Y
Gaucher, C. (2009) N Y Y Y Y U U U Y Y
Hung, C.C. (2008) N Y Y Y Y U N Y Y Y
Krenkova, P. (2009) N Y Y Y Y N U Y Y Y
Krypuy, M. (2006) N Y Y Y Y Y U U Y Y
K r y p u y , M . F F ( 2 0 0 7 ) N Y Y YY Y YYYY
Krypuy, M. FFPE (2007) N Y Y Y Y Y U U Y Y
Liyanage, K.E. (2008) N Y Y Y Y Y YYYY
Lopez-Villar, I. (2010) N Y Y Y Y Y U U Y Y
Ma, E.S. (2009) N Y Y Y Y Y N Y Y Y
Nomoto, K. (2006) N Y Y Y Y Y U Y Y Y
Olsen, R.K. (2010) N Y Y Y Y Y YYYY
Pichler, M. (2009) N Y Y Y Y Y YYYY
Polakova, K.M. (2008) N Y Y Y Y Y U U Y Y
Rapado, I. (2009) Y Y Y Y Y Y U U Y Y
Simi, L. (2008) N Y Y Y Y Y U U Y Y
Takano, T. (2007) N Y Y Y U U Y U Y Y
Tan, A.Y. (2008) N Y Y Y Y Y U U Y Y
van Eijk, R. (2010) N Y Y Y Y Y U U Y Y
Whitehall, V. (2009) N Y Y Y Y Y U U Y Y
Willmore, C. (2004) N Y Y Y Y N U U Y Y
Willmore-Payne, C. (2005) N Y Y Y Y Y U Y Y Y
Willmore-Payne, C. (2006
LC)
NYYY YNU Y Y Y
Willmore-Payne, C. (2006) N Y Y Y Y N U Y Y Y
Xiao, J. (2009) N Y Y Y Y U U U Y Y
XinHui,Fu. (2009) N Y Y Y Y Y U U Y Y
YongPing,Lu. (2010) N Y Y Y Y U U U Y Y
ZhiHong,Chen. (2010) N Y Y Y Y Y U U Y Y
Y=yes; N=no; U=unclear;
1reference standard included sequencing and pyrosequencing; LC: lung cancer.
Items: 1) Was the spectrum of patients representative of the patients who will
receive the test in practice? 2) Were the selection criteria clearly described? 3) Is
the reference standard likely to classify the target condition correctly? 6) Did
patients receive the same reference standard regardless of the index test result?
8) Was the execution of the index test described in sufficient detail to permit
replication of the test? 9) Was the execution of the reference standard
described in sufficient detail to permit replication? 10) Were the index test
results interpreted without knowledge of the results of the reference standard
result? 11) Were the reference standard results interpreted without knowledge
of the results of the index test? 13) Were uninterpretable/intermediate test
results reported? 14) Were withdrawals from the study explained?
doi:10.1371/journal.pone.0028078.t001
Table 2. Result of the multivariable meta-regression model
for the most important characteristics with backward
regression analysis (Inverse Variance Weights).
Variable Coeff. Std. Err. p - value RDOR [95%CI]
Cte. 1.838 0.9233 0.0516 - -
S 20.629 0.1301 0.0000 - -
Instrument type 0.440 0.2573 0.0930 1.55 (0.93; 2.60)
Sample size 2.577 0.5975 0.0001 13.15 (3.97; 43.57)
doi:10.1371/journal.pone.0028078.t002
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tissue, formalin-fixed and paraffin-embedded (FFPE) tissue or
cytologic slides), eligible/non-eligible sample size (eligible (.35
samples/amplicons with mutations and .35 samples/amplicons
without mutation to yield 95% confidence intervals whose lower
boundary is .90% sensitivity if the sensitivity is 100%) [39] and
non-eligible (all other samples), disease type (tumorous or non-
tumorous), study site (Europe, Asia, Oceania or North America),
mutation type (TP53, EGFR, KRAS or others), study language
(Chinese or English), design type (single-gate design or two-gate
design) and answers from the 10 questions of the QUADAS
quality assessment tool. Variates were considered as explanatory if
their regression coefficients were statistically significant (P,0.05).
Subsequently, we developed a multivariable regression model and
using a backward stepwise algorithm, we identified the most
important characteristics. Characteristics were retained in the
regression model if P,0.05.
Subgroup analyses
Subgroup analyses were planned a priori depending on the
following: (1) most important characteristics as selected via meta
regression, (2) instrument type (HR-1 or other instrument), (3) dye
type (EvaGreen, LCGreen I, LCGreen plus, Resolight or Syto9)
and (4) sample source (blood/bone marrow cell, FF tissue, FFPE
tissue or cytologic slides).
Results
Literature search outcome
The results of the literature search and the stepwise exclusion
process are illustrated in Figure 1. Out of 195 references found,
only 34 articles met our inclusion criteria. These articles were
divided into 58 ‘units’ for statistical analysis according to target
fragment/mutation-type and sample source (Table S1). Of the 161
publications excluded, 22 were for non-human HRMA studies,
such as viruses, bacteria, mosquitoes and other animals, 15 were
non-HRMA studies applied to the human genome, 15 were
studies where HRMA was used as part of other research methods,
seven used multiple probes, eight combined HRMA with qPCR or
other methods, 11 were not original research studies, one was a
conference presentations, eight were reviews, two were letters, 32
were not for performance evaluation studies of HRMA, 27 were
not of HRMA applied to mutation detection (20 SNPs, 4
methylation and 3 others), 14 did not exclusively use sequencing
as the reference standard (8 dHPLC, 1 DGGE and 5 mixed
methods) and 25 only applied sequencing to HRMA positive
results. Amplicon size varied from 51–634 bp and the most
common sample source was FFPE. The most frequently used dye
was LCGreen I and the most commonly used instrument was the
LC480.
Study description
The 34 studies included in the meta-analysis included reports on
theevaluationof the accuracy ofHRMA forthedetectionof human
disease-associated mutations (Table S1). Instrument types included
HR-1 [15,16,19,40–45] (n=9), LightCycler480 [13,17,18,20,22,
46–55] (n=14), RotorGene6000 [13,56–62] (n=8) and Light-
Scanner96 [63–65] (n=3). There were 27 single-gate designs and 7
two-gate designs. Disease types included 27 tumorous and seven
non-tumorous diseases. The total answers to the QUADAS quality
assessment tool included, ‘yes’ 251/350 (71.7%) and ‘unclear/
no’99/350 (28.3%) (Figure 2). The study sites were distributed over
4 continents including Europe (10 total, 3 Spain, 1 Netherlands, 2
Italy, 2 Czech Republic, 1 Denmark, 1 France) Asia (9 total, 4
Figure 1. Flowchart for the selection of articles for meta-analysis.
doi:10.1371/journal.pone.0028078.g001
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(7 total, all USA). Only three of the five studies carried out in China
were Chinese language publications [55,61,63].
Summary estimates of sensitivity, specificity, LR and DOR
The pooled sensitivity and specificity estimates were 97.5%
(95% confidence interval (CI): 96.8–98.5; I
2=27.0%) and 95.8%
(95% CI: 95.3–96.3; I
2=91.6%), respectively (Figure S1). The
results from the analysis of all the pooled manuscripts are also
shown in Table 3.
Meta-regression analysis
After single factor regression analysis, two variables were found
to be explanatory: sample size and instrument type. Therefore, we
developed a multivariable regression model using a backward
stepwise algorithm to evaluate sample size and instrument type as
variables. From this regression model, sample size was determined
to be the most important characteristic (Table 2).
Subgroup analysis
For the subgroup analysis of sample size and instrument type,
the sensitivity of the eligible sample size subgroup was 99.3% (95%
CI: 98.1, 99.8; I
2=0.0%), non-eligible sample size subgroup was
96.6% (95% CI: 94.9, 97.8; I
2=19.9%), other instruments
subgroup was 98.7% (95% CI: 97.7, 99.3; I
2=0.0%) and HR-1
instrument subgroup was 95.1% (95% CI: 92.0, 97.2; I
2=53.1%)
(Table 3). The sensitivity of the eligible sample size and other
instruments subgroups were significantly higher than the non-
eligible sample size and HR-1 instrument subgroups, respectively
(P,0.0001, Figure S2 and Figure S3). The specificity of the
eligible sample size subgroup was 93.4% (95% CI: 91.7, 94.9;
I
2=92.2%), non-eligible sample size subgroup was 96.2 (95% CI:
95.7, 96.7; I
2=96.2%), other instruments subgroup was 95.4%
(95% CI: 94.9, 95.9; I
2=93.2%) and HR-1 instrument subgroup
was 99.5% (95% CI: 98.6, 99.9; I
2=7.1%). The specificity of the
eligible sample size and other instruments subgroups were
significantly lower than the non-eligible sample size and HR-1
instrument subgroups, respectively (P,0.0001, Figure S2 and
Figure S3) but there were was no difference among other
instruments within the other instruments subgroup (data not
shown). No significant differences were detected in dye type and
sample source subanalyses (data not shown).
The PRISMA 2009 checklist is provided as Checklist S1.
Discussion
In this systematic review, we obtained summary estimates for the
diagnostic accuracy of HRMA in the detection of disease-associated
Figure 2. Assessment of quality items using modified QUADAS tool. Y=yes; U=unclear; N=no.
doi:10.1371/journal.pone.0028078.g002
Is HRMA Accurate for Detecting Mutations?
PLoS ONE | www.plosone.org 5 December 2011 | Volume 6 | Issue 12 | e28078mutations in humans. HRMA was found to be a high sensitive
modality when compared with DNA sequencing.
It has been previously shown that studies of diagnostic
performance of modalities with methodological shortcomings
may lead to overestimates of the accuracy of the diagnostic test
[66]. In this study, meta-regression analysis was used to evaluate
the effect of different study characteristics, such as sample size,
instrument type and dye type, on the diagnostic performance of
HRMA. The advantage of the regression analysis performed here
is that the model accounts not only for the heterogeneity between
studies from different threshold settings but also for the error of
estimation of the sensitivity and specificity values in each study.
This random model also accounts for the residual heterogeneity
that may remain even after adjusting for individual study
characteristics and HRMA technical conditions [67]. The results
of the meta-regression analysis indicated sample size was the most
significant characteristic influencing diagnostic accuracy.
Data from the subgroup analysis indicated differences for
sample size. After studies were divided into eligible sample size and
non-eligible sample size subgroups, the heterogeneity was
significantly decreased. The eligible sample size subgroup of
studies had significantly higher sensitivity and was less heteroge-
neous that the non-eligible sample size subgroup. These
improvements may result from differences in the prevalence of
samples/amplicons with mutations, as the number of mutations in
the eligible sample size subgroup was significantly higher (550/
1543, 35.6%), than the non-eligible sample size subgroup (697/
6274, 11.1%). Therefore, the results showed that the number of
samples with/without mutations in a study has an important
influence on diagnostic accuracy [39].
Although the multivariable regression analysis presented here
showed that the instrument type was not a significant character-
istic, previous studies have shown that instrument type does affect
the sensitivity and specificity of HRMA [11,68–71]. The subgroup
analysis of instrument type indicated some differences. For
example, other instruments were more sensitive than the HR-1
instrument. This may be because the other instruments were some
of the latest real-time thermal cyclers modified to incorporate
Table 3. Summary results of the pooled and subanalysis by meta disc 1.4.
Statistical
Index Pooled Sample Size
Q Instrument Type
W
Eligible
a Non-eligible HR-1 Other
1
Sensitivity
(%)
97.7 99.3 96.6 95.1 98.7
(96.8, 98.5) (98.1, 99.8) (94.9–97.8) (92.0, 97.2) (97.7, 99.3)
Cochran’s 0.034 0.551 0.119 0.008 0.682
Q (P value)
I
2 27.0% 0.0% 19.9% 53.1% 0.0%
Specificity 95.8 93.4 96.2 99.5 95.4
(%) (95.3, 96.3) (91.7, 94.9) (95.7, 96.7) (98.6, 99.9) (94.9, 95.9)
Cochran’s ,0.0001 ,0.0001 ,0.0001 0.373 ,0.0001
Q (P value)
I
2 91.6% 92.2% 91.6% 7.1% 93.2%
LR + 34.72 28.51 37.82 32.06 32.24
(22.37, 53.90) (9.80, 82. 92) (22.61, 63.24) (17.61, 58.37) (19.88, 52.26)
Cochran’s ,0.0001 ,0.0001 ,0.0001 0.539 ,0.0001
Q (P value)
I
2 87.2% 93.2% 85.2% 0.0% 89.0%
LR 2 0.07 0.02 0.10 0.10 0.06
(0.05, 0.09) (0.01, 0.04) (0.08, 0.13) (0.06, 0.17) (0.04, 0.08)
Cochran’s 0.132 0.95 0.815 0.078 0.780
Q (P value)
I
2 17.4% 0.0% 0.0% 36.5% 0.0%
DOR 711.75 2198.5 522.16 634.96 816.23
(427.18, (735.39, (304.06, (262.66, (431.39,
1185.9) 6572.6) 896.72) 1535.0) 1544.2)
Cochran’s 0.031 0.31 0.102 0.829 0.004
Q (P value)
I
2 27.2% 14.4% 21.2% 0.0% 39.5%
1: Other instruments included LightCycler480, Rotor-Gene6000, LightScanner96;
W: the sensitivity of the eligible and other instruments groups were significantly higher than the non-eligible and HR-1 groups, while the opposite relationship was
observed for specificity (P,0.0001).
a:( .35 samples/amplicons with mutations and .35 samples/amplicons without mutations are needed to yield 95% confidence intervals whose lower bound is .90%
sensitivity if the sensitivity is 100%).
doi:10.1371/journal.pone.0028078.t003
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slower than the HR-1 instrument [25].
We found that HRMA was a highly sensitive method for
mutation detection that yielded low negative LR without
substantial heterogeneity. The sensitivity of all publications in
the study, the eligible/non-eligible sample size subgroup and other
instruments subgroups were 97.5%, 99.3%/96.6% and 98.7%,
respectively and the negative LR were 0.07, 0.02/0.10 and 0.05,
respectively. These results compare well with a recent compilation
of 19 studies for constitutional variants that found an overall
sensitivity of 99.3% (n=5839) [72]. The high sensitivity of HRMA
means that the technique can be considered as SnNOut (high
sensitivity, negative, rules out) [73–75]. In this scenario, a negative
HRMA test result rules out mutations. Therefore, when
implemented correctly, the need for subsequent sequencing
disappears for the pooled group (sensitivity 81.0%, 6322/7817,
32 false negatives), and the other instruments (sensitivity 82.2%,
5726/6967, 12 false negatives) and non-eligible sample size
subgroups (sensitivity 85.6%, 5373/6274, 25 false negatives).
These results are consistent with Provaznikova et al. [76] who
reported avoiding unnecessary sequencing of more than 85% of
the MYH9 gene. HRMA takes only a few minutes and costs only
11% of the cost of sequencing one exon [28], significantly reducing
costs and saving time. However, in the eligible sample size
subgroup, the reduction of sequencing is less (61.5%, 949/1543, 7
false negative) due to the greater number of mutations. Thus, the
results showed HRMA is more suitable for screening for lower
incidence mutations.
In general, as the sensitivity of diagnostic tests improves, the
specificity decreases. Therefore, the specificity of the eligible
sample size and other instruments subgroups was significantly
lower than the non-eligible sample size and HR-1 subgroups.
Specificity was homogeneous in the HR-1 instrument subgroup.
This may be due to the fact that most of the samples were from
only two research institutions (635/933 units of statistical analysis).
However, the overall specificity of HRMA showed considerable
heterogeneity between studies. This may be related to additional
factors, such as the sequence length, GC content and sequence,
that are properties of the individual sequences under study [77–
79]. Other factors that are independent of the sequence, such as
the presence of substances such as DMSO or betaine [80,81], may
also affect specificity. It is difficult to quantitatively analyse these
factors.
In addition, we found that the sample source and dye used had
no impact on HRMA accuracy. This is contrast to previous studies
that found that the sample source and dye used affected HRMA
accuracy [15,20,22,41,72]. The discrepancies between studies may
result from differences in sample size, the focus of the researchers
and/or the methods of statistical analysis. The continent of origin,
design type and diagnostic accuracy also showed no significant
effect in the meta-regression analysis.
In this study, amplicon length had some impact on the
sensitivity and specificity of HRMA, as in previous reports
[23,82]. For example, for PCR products of less than 400 bp,
sensitivity and specificity were 100%. While for PCR products
400–1000 bp long, the sensitivity was reduced to 96.1% and
specificity to 99.4%. In this study, the majority of amplicon lengths
were in the recommended amplicon length range (less than
300 bp) [23]. Therefore, the impact of amplicon length was not
investigated further here. Many factors, including sequence-
dependent and non-sequence dependent factors, affected HRMA
accuracy. Therefore, standardization of DNA preparation, PCR
and HRMA operating procedures are essential. Also, it remains
necessary to subsequently sequence positive results from HRMA
for confirmation. The current meta-analysis has some limitations
in that the studies were heterogeneous and most studies used small
sample sizes. In addition, the effect of language selection bias and
literature type cannot be ignored as we only chose published
articles in Chinese and English. In order to avoid this bias, the
search should not be language limited and all literature types
should be searched. However, most of the articles found on
HRMA were published in English so the language bias was
minimized. The selection bias was further minimized by
maximizing the sensitivity of the search words, performing the
search over a long search time and using a variety of databases/
search engines including Medline, Embase, Cochrane Library,
Medion, CBMdisc, Sciencedirect, SUMsearch, Google, Database
for Chinese Journals of Technology (Chinese) and selected Journal
Special Issues. In addition, the reference lists from articles
obtained from the automated searches were checked manually.
Publication bias is a potential limitation of any systematic
review. Smaller studies are associated with a greater diagnostic
accuracy [83]. However, studies about publication bias focus
mostly on randomized trials, and these types of studies are
registered. The registration of studies for diagnostic studies is
either limited or difficult to achieve. Due to the smaller sample
sizes used for diagnostic studies, fewer studies were identified by
the searches were for inclusion in this review. We examined
publication bias by assessing whether the sample size of studies was
associated with diagnostic accuracy, and found an association
between sample size and HRMA diagnostic performance in the
subgroup analysis. Therefore, assessment of the effect of sample
size on HRMA accuracy was not ignored in further studies. In
addition, there was no consistent relationship between language
restriction and publication bias [83].
In conclusion, the sensitivity, simplicity, and low cost of HRMA
make it the method of choice to screen patients for disease-
associated variants, especially those diseases with lower incidence
mutations. HRMA sensitivity is higher in the eligible sample size
subgroup and is affected by instrument type but not by sample
source or dye type. The DNA sequencing burden can be
significantly reduced by the implementation of HRMA, but
positive results still require sequencing for diagnostic confirmation.
Further clinical studies of HRMA need to pay attention to the
impact of sample size on diagnostic accuracy. However, as HRMA
is still a relatively new technology, increases in accuracy can be
expected as the diagnostic technology improves with time.
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